High throughput affinity and functional screening
Orbit have generated technologies to significantly improve the throughput for screening biological molecules for affinity and function. Our mission is to use high throughput affinity and functional screening to address challenging targets that have been difficult to drug.
Orbit was founded By Professor Terry Rabbitts and Professor Graham Ogg in 2015 as a spin-out from the University of Oxford. The company’s focus is to identify therapeutic peptides using its unique peptide display platform. In 2021 the organisation spun out its drug discovery programs and established Orbit Discovery Ltd as a therapeutic peptide drug discovery service provider.
Orbit Discovery will focus on the identification of peptide therapeutics to any target that exhibits interesting biology. The company has built up extensive expertise in the purification of complex membrane proteins and aims to become the leader in identifying peptide agonists and antagonists to GPCRs